Stopping rules for clinical trials.
We describe a new method of formulating stopping rules for clinical trials, one that incorporates opinion on what difference is clinically important. We compare the method with conventional group sequential designs and illustrate it by application to a study of Pancuronium Bromide for prevention of haemorrhage in pre-term infants.